Stocks to Watch: Vallon Pharmaceuticals, Icosavax, Kaspien Holdings

Dow Jones2022-12-14
 

By Kathryn Hardison

 

Vallon Pharmaceuticals Inc. agreed to merge with GRI Bio Inc., a privately-held biotech, in an all-stock deal. The combined company will focus on T cell regulators for the treatment of inflammatory, fibrotic and autoimmune diseases. Vallon shares surged 154% in after-hours trading on Tuesday.

 

Icosavax Inc. said new data from a trial of its IVX-121 vaccine has demonstrated a sustained neutralizing antibody response against the respiratory syncytial virus, lasting for at least six months after a single dose. Shares rallied 11% in after-hours trading.

 

Kaspien Holdings Inc. posted a wider third-quarter loss and lower revenue. The e-commerce marketplace's revenue fell to $29.1 million, which the company said was due to declines in fulfillment by Amazon.com Inc. in the U.S. Shares dropped 29% in after-hours trading, reversing course after the stock gained 35% during the day.

 

Write to Kathryn Hardison at kathryn.hardison@wsj.com

 

(END) Dow Jones Newswires

December 13, 2022 18:23 ET (23:23 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment